Plasma proteomic analysis in patients with idiopathic pulmonary fibrosis (IPF) from a phase 2 trial of admilparant - Amsterdam 2025

Top scoring: bench to bedside in pulmonary fibrosis

Chair(s): GEORGE MARGARITOPOULOS, David Smith

Session type: Oral presentation

Plasma proteomic analysis in patients with idiopathic pulmonary fibrosis (IPF) from a phase 2 trial of admilparant

Toby M Maher

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Autoantibody reduction treatment for acute exacerbations of idiopathic pulmonary fibrosis.

Steven Duncan

Replay

Poster

Abstract

Slides

Integrated spatial and single-cell transcriptomics reveal PAK kinase as a therapeutic target in fibroblastic foci and dense fibrosis of IPF

Yuta Hirano

Replay

Poster

Abstract

Slides

The PPFE atlas reveals distinct profibrotic and elastotic mesenchymal cellular archetypes in pleuroparenchymal fibroelastosis

Jannik Ruwisch

Replay

Poster

Abstract

Slides

The transcriptome of CD14+CD163-HLA-DRlow monocytes predicts mortality in Idiopathic Pulmonary Fibrosis

Theodoros Karampitsakos

Replay

Poster

Abstract

Slides

The early-stage lung immune infiltrate in patients with Idiopathic Pulmonary Fibrosis differentiate stable and progressive disease

Tamara Cruz Santa Cruz

Replay

Poster

Abstract

Slides

GM-CSF-engineered cell vaccine based on myofibroblast for the treatment of pulmonary fibrosis

Minyang Fu

Replay

Abstract

Slides

Intranasal MAF peptide vaccine for idiopathic pulmonary fibrosis therapy

Jiayu Wang

Replay

Abstract

Slides

Vaccination targeting ephrin-B2 ameliorates established pulmonary fibrosis

Jian Liu

Replay

Abstract

Slides

Plasma proteomic analysis in patients with idiopathic pulmonary fibrosis (IPF) from a phase 2 trial of admilparant

Toby M Maher

Replay

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}